StemCell Therapy

Pune, India, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The global regenerative medicine market size is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. The market was valued at US$ 23,841.5 Million in 2018. Fortune Business Insights states that the market will reach US$ 151,949.5 Million by the end of 2026, thereby exhibiting a CAGR of 26.1%. North America generated maximum revenue of US$ 9,128.2 Million in 2018 and is expected to dominate the global regenerative medicine market throughout the forecast period. Due to presence of substantial number of key market players based in U.S., presence of research institutes involved in development of novel therapeutics and availability of advanced technologies are attributive to the high number of clinical trials in North America.

Key Industry Developments:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Increasing Investment in R&D of Regenerative Medicine to Enable Growth

The growing investment in research and development of regenerative medicine has made a significant contribution to the growth of the global market. The increasing investment from private as well as government organizations has had a positive impact on the global market. IN March 2018, SanBio collaborated with Hitachi Chemical Advanced Therapeutics Solutions for developing regenerative medicine across a wide range of applications.

Novartis Receives EU Approval for Luxturna

The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to treat severe life-threatening diseases in an efficient manner has created a huge demand for the products across the world. Increasing drug approvals have contributed to the rising uptake for regenerative medicines.

Click here to get the short-term and long-term impact of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

In 2018, Novartis received usage approval from the European Union for its latest regenerative medicine Luxturna. The drug was used to treat and restore sight for people with vision impairment. Luxturna was widely useful in treatment of rare retinal diseases.

Integra LifeSciences Latest Product Offering Will Favor Market Growth

The advancements in regenerative medicine have fueled their demand across the world. Increasing product launches have contributed to the rising uptake of regenerative medicine across the world. In 2017, Integra LifeSciences announced the launch of Integra Dermal Regeneration Template Single Layer Thin.

Fortune Business Insights some of the leading companies that have made significant growth contributions to the global market. Besides this, the report identifies some of the attractive business strategies that have been adopted by renowned companies in the world.

Quick Buy - Regenerative Medicine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100970

List of the leading companies that are operating in the Regenerative Medicine Market:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/regenerative-medicine-market-100970

Global Regenerative Medicine Market Segmentation:

By Product

Cell Therapy

Gene Therapy

Tissue Engineering

Platelet Rich Plasma

By Application

Orthopedics

Wound Care

Oncology

Others

By Distribution Channel

Hospitals

Clinics

Others

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexico and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/regenerative-medicine-market-100970

SECONDARY DATA SOURCES THAT WE REFER TO:

Have a Look at Related Reports:

Bovine Lactoferrin Market Share Trends & Industry Analysis, By Product (Spray-dried, and Freeze-dried), By Application (Infant Formula, Pharmaceuticals, Dietary Supplements, Food, and Others), and Regional Forecast, 2019-2026

Knee Replacement Market Share & Industry Analysis, By Procedure (Total Knee Arthroplasty, Partial Knee Arthroplasty, and Revision Arthroplasty) By Implant Type (Fixed Bearing, Mobile Bearing, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2019-2026

Electrophysiology Devices Market Share & Industry Analysis, By Type (Ablation Catheters, Diagnostic Catheters, Mapping Systems, Accessories & Others), By Application (Atrial Fibrillation, Supraventricular Tachycardia (SVT), Ventricular Tachycardia, and Others), By End User (Hospitals & ASCs, and Specialty Clinics & Diagnostic Centers), and Regional Forecast, 2019-2026

Vaccines Market Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026

Prefilled Syringes Market Share & Industry Analysis, By Material (Glass and Plastic) By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System) By Product (Complete Syringe Set and Components & Accessories) By Design (Double-chamber, Multiple-chamber, and Single-chamber) By End-user (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others) and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/regenerative-medicine-market-9183

Read more from the original source:
Global Regenerative Medicine Market to Rise Impressively at 26.1% CAGR and Hit USD 151,949.5 Million by 2026; Integra's Latest Product Offerings to...

CureDuchenne is a global nonprofit honed in on discovering a cure for Duchenne muscular dystrophy (DMD). Its funding arm, CureDuchenne Ventures, is investing in regenerative medicine firm Mesentech, as part of a joint funding collaboration with the Charles H Hood Foundation (which seeks to advance early-stage research for pediatric conditions).

CureDuchenne Ventures, the funding arm of CureDuchenne (a nonprofit aimed at discovering a cure for Duchenne muscular dystrophy) is investing in Mesentech Inc., a regenerative medicine company with a prodrug platform that selectively delivers therapeutics to bone. The project is part of a new joint funding collaboration with the Charles H. Hood Foundation (CHF), which seeks to advance early-stage research for pediatric conditions.

Lianna Orlando, CureDuchennes senior director of research, told Outsourcing-Pharma that bone fractures and quality of life are the top two main outcome measures identified by people with DMD.

Individuals with Duchenne are at a high risk for osteoporosis for multiple reasons that include reduced weight-bearing activity (which normally drives development of strong and dense bones), as well as a side-effect of glucocorticoid therapy, and from the effect of the chronic inflammatory response seen in dystrophin-deficient muscles, she said. Fractures in the vertebral bones of the spine are seen in up to 30% of boys with Duchenne, and in addition to being very painful may lead to spine deformity; fractures in the long bones in the arm or the leg are common, and in many cases lead to permanent loss of ambulation.

Whats more, she said, bone fractures can lead to additional complications.

Long bone fractures can release fat emboli into the bloodstream, which can obstruct blood flow in critical places, including the lungsmost often the lungs. Although rare, fat embolism syndrome is a particularly serious complication of bone fractures in Duchenne; in the most severe cases, fat embolisms can lead to death, Orlando told OSP.

The CureDuchenne investment supports Mesentechs lead program, MES-1007, into clinical development and its evaluation in DMD. There are currently no approved therapies for bone wastage for individuals affected by DMD.

Debra Miller, founder and CEO of CureDuchenne, said the investment and collaboration hold the potential to increase the groups impact.

Addressing bone morbidities that contribute to the loss of ambulation could significantly add quality of life to everyone affected by Duchenne, said Miller.

In addition to providing Mesentech with funding, CureDuchenne intends to play an active role in advancing the prodrug technology platform for DMD. Additionally, CureDuchenne chief scientific officer Michael Kelly will join Mesentechs scientific advisory board.

See more here:
Rare-disease foundation backs regenerative research - OutSourcing-Pharma.com

Newswise LOS ANGELES (Dec. 1, 2020) -- Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences. Chute assumed his new post Nov. 23.

The selection of Chute, following a national search, reflects the importance of his pioneering research in blood-forming stem cells called hematopoietic stem cells, which can self-renew and generate all cell types found in the blood and immune system. Over the past decade, Chute's lab has discovered several growth factors produced by the cells that line the walls of blood vessels; they play a critical role in blood-forming stem cell regeneration.

"Dr. Chute is an exceptional addition to our faculty," saidDanTheodorescu, MD, PhD, director ofCedars-Sinai Cancer. "His international reputation as a physician-scientist who has made major contributions to stem cell and hematopoietic cell biologywill greatly contribute to positioning the newly created Division of Hematology and Cell Therapy as one of the best in the nation, while providing Cedars-Sinai Cancer patients with exciting new options for the treatment of blood malignancies."

In addition to his hematopoietic stem cell research, Chute said he looks forward to expanding Cedars-Sinai's CAR T-cell research and therapy. He describes the immune-boosting therapeutic as "transformative" for patients with advanced non-Hodgkinlymphoma,childhood acute lymphoblastic leukemiaand potentially several additional blood cancers.

CAR T-cell therapy is a type of immunotherapy in which patients' own immune cells, called T cells, are collected from their blood, and then an artificial receptor chimeric antigen receptor, or CAR is added to the cells' surface. The receptor enables the modified cells to specifically eradicate cancer cells. The cells are infused back into a patient's body intravenously, where they multiply and attack tumor cells.

"CAR T therapy has become an important treatment option for so many patients with advanced cancer who had no options before," Chute said. "That's what makes CAR T therapy so exciting."

Chute joins Cedars-Sinai from the David Geffen School of Medicine at the UCLA, where he was a professor of Medicine and Radiation Oncology in the Division of Hematology/Oncology and an investigator in the Broad Stem Cell Research Center.

Chute earned his medical degree at Georgetown University. He completed his residency in internal medicine and fellowship in Hematology/Oncology at the National Naval Medical Center. He completed his research training at the National Cancer Institute and the Naval Medical Research Institute.

"I'm excited to join the Cedars-Sinai Cancer faculty because of the opportunity to collaborate with the world-class scientists and top-tier physicians at the cancer center," Chute said. "Cedars-Sinai has always been a leading medical center and is deeply committed to basic and translational research, while also growing the hematology and cellular therapy specialties. I'm eager to play a leading role in that growth."

Clickhereto read more from the Cedars-Sinai Newsroom.

Excerpt from:
Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise

BABIES!

Most people love babies and want a few at some point in their life. But for about 30 million infertile couples in India, alone, babies are an out-of-reach pipe dream.

When Vasanthi Palanivel, a biotech scientist with two decades of experience, saw her friend, Srinivas Chari and his wife undergoing issues with conceiving a baby - and the immense grief that failed treatments caused - she decided to do something about it.

Vasanthis work in the biotech space focused specifically on tissue engineering and stem cell-based treatments, and she decided to use that expertise to develop a regenerative medicine-based infertility treatment, which she claims is better than most traditional treatments available today.

Fertility treatments are expensive - around Rs 1 lakh to Rs 1.25 lakh, per cycle, according to price ranges outlined online by leading IVF treatment centres, have low success rates, and, more importantly, are not covered by insurance. Only a percent of the 30 million infertile couples in India seek IVF treatments, and most of them target very specific problems with synthetic solutions, instead of restoring the patients health, holistically.

She says plasma-based treatments offer breakthroughs where traditional medicine has limited scope. Regenerative treatments are also generally safer, fast-acting, and go beyond just treating the symptoms and problem areas - they help restore organs, tissues and muscles to their ideal state so that the body can function as its supposed to.

So far, the startup has raised angel funding from several individual investors, and is open to more investments. Vasanthi, whos also the startups Chief Scientific Officer, says the venture is profitable, and growing at 100 percent, year on year.

Seragen, founded in 2018, treats over 10 conditions related to male and female infertility, including repeated miscarriages, low testosterone, erectile dysfunction, hormonal imbalance and endometriosis, among others.

The startup gets most of its clients via doctor referrals. On a pre-determined date, the patients case history detailing their medical condition, and their blood sample is collected by Seragens laboratory. The scientists then concoct a personalised fertility medicine, specific to the patients condition, and then send it back to the doctor for administering.

Image credit: Shutterstock

The process takes around 45 minutes, and the medication kicks in roughly 48 hours later.

The cost of the treatment is less than 10 percent of current fertility treatments, she adds.

So far, Seragen has treated over 2,000 patients. Its most requested treatments are for ovarian failures and endometrium. Women over 35 form a large part of the startups patient base.

Currently, the firm is piloting an immunology-based protocol with Indira IVF to target miscarriages - and Vasanthi says she hopes to publish encouraging results soon. The company is also working on a treatment to help prevent the death of mothers after they give birth.

Present in several cities in India already, Seragen is aiming to strengthen its presence domestically, as well as internationally. The startup says it will start operating in South Asian countries like Sri Lanka and Seychelles soon.

The startup competes with generic infertility treatment providers, as well as some stem cell-based therapy providers.

The global regenerative market is expected to reach $17.9 billion by 2025, from $8.5 billion in 2020, and growing at a CAGR of 15.9 percent, a Markets and Markets research report showed. Chronic diseases, genetic disorders and cancers, as well as rising investments in regenerative medicine research is expected to drive most of the growth, the research said.

More:
How biotech startup Seragen is reworking infertility treatments with regenerative therapies - YourStory

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

See original here:
Resolution Therapeutics Announces a 26.6m Series A Financing from Syncona Ltd - PharmiWeb.com

VALENCIA, Calif, and MELBOURNE, Australia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.

Kathys extensive healthcare experience and industry insight are a welcome addition to AVITAs leadership team, said Dr. Mike Perry, AVITA Therapeutics Chief Executive Officer. In particular her broad operational experience within Regenerative Medicine will be critically important as we seek to bring our pipeline products through development and into the markets.

Ms. McGee joins AVITA with over 25 years of biopharmaceutical and life sciences experience, most recently serving as President of CnA Consulting Group, which focuses on providing specialized consulting services to the life sciences industry. Prior to CnA Consulting, Ms. McGee was the Vice President of West Coast Operations at Shire Pharmaceuticals Regenerative Medicine Division, formerly Advanced BioHealing, where she was a part of the leadership team responsible for manufacturing operations, strategic planning, capital expansion, and real estate. At Advanced BioHealing, Ms. McGee served as the Senior Vice President of Operations and General Manager, with responsibility for the companys manufacturing operations in La Jolla, CA. She has also held senior Operations leadership roles at Smith and Nephew and Advanced Tissue Sciences. She earned her Bachelor of Science in chemistry and mathematics from University College Galway Ireland, and holds a Masters degree in Business and Management from Webster University.

Authorized for release by the Chief Executive Officer of AVITA Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

Story continues

AVITA Therapeutics first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

Continued here:
AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer - Yahoo Finance

PARIS--(BUSINESS WIRE)--EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised 1.1 million in funding from institutional and private investors to develop its exosome bioproduction platform. This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022.

Towards the emergence of new therapeutics in regenerative medicine

Exosomes are biological nanoparticles released by cells as an intercellular communication system to transport biomolecules. They have the ability to deliver therapeutics or regenerate tissue in several pathologies, including osteoarthritis, heart failure, and liver and kidney diseases, conditions which impact more than 150 million patients worldwide. Exosomes are now considered one of the safest and most promising future regenerative therapy solutions. They are also easy to store and have a low immunogenic profile, thus reinforcing their potential.

Increasingly, academic and industrial players are working on the therapeutic potential of exosomes. The main obstacle to the translation of exosomes into clinical development is industrial manufacturing while maintaining robust quality and reproducibility.

EVerZom's proprietary innovation consists in applying turbulence stimulation on cells to trigger massive exosome release. This approach enables the production of ten times more exosome ten times more rapidly than classical methods. The technology is being developed and already implemented in GMP certified systems, simplifying the clinical transfer.

This technology and the know-how developed around exosomes allows EVerZom to offer a scalable and reproducible exosome production process with robust quality controls. Everzom's internal R&D is continuing its work on the link between the qualification of exosomes and their application potential. EVerZom's ambition is to become the European leader in the bioproduction of exosomes.

"We are delighted with this financing opportunity, which will enable us to industrialize our proprietary technology and meet the growing demand of the exosome market. Our ambition is to foster the emergence of new exosome therapeutic strategies and to make them accessible to the largest possible number of patients as quickly as possible" explains Jeanne Volatron, Co-founder and President of EVerZom. http://www.everzom.com

Excerpt from:
EVerZom Raises 1.1M to Industrialize Its Exosome Biomanufacturing Platform - Business Wire

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1889<ype=S

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Original post:
Regenerative Medicine Market to Witness Steady Expansion During 2025 - Murphy's Hockey Law

The Regenerative Medicine Market Industry report shields a thorough investigation towards the competitive profile encompassing the market stake along with company outline of the major contributors functioning in the global Regenerative Medicine market. The market report offers a comprehensive summarization of product description, product type, technological development as well manufacturing analysis including cost, income, and gross analysis. The market comprises of past data related to growth rate, market price, volume and futuristic analysis of the Regenerative Medicine market.

Moreover, it describes factors that are responsible for influencing for the growth of the Regenerative Medicine market, demand, and supply as well as the challenges and opportunities tackled by the competitive Regenerative Medicine market. In addition, the report holds important information for the Regenerative Medicine market players that enables them to understand the overall market scenario and expand their Regenerative Medicine Market business stats.

The report covers a number of the players in the Regenerative Medicine market, including:

Integra LifeSciences Corporation; MiMedx Group, Inc.; AstraZeneca; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Pfizer Inc.; and Baxter.

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/52

The Regenerative Medicine market report delivers screen-shot of major competitors, market tendencies together with the forecast over the next five years, with anticipated growth rates and the major factors impacting and driving growth, the market statistics and Regenerative Medicine Market Industry information resulting from the various blending of primary and secondary sources.

Global Regenerative Medicine Market Report tracks the all the significant market occasions. Social occasion of data from different fields and through proper discoveries, the report has firmly anticipated development of the worldwide Regenerative Medicine market including regions and different section.

Key points considered in the Regenerative Medicine market report: company profile, production cost structure of market, sales and income analysis of Regenerative Medicine market, production scrutiny by geological region, Regenerative Medicine market strategies considering the major aspects related to restraint, opportunities, driving factors, challenges and possible analysis of new Regenerative Medicine market projects and their investment structure.

Read complete report @ https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

The Global Regenerative Medicine market focuses on the major factors mentioned below:

1.A comprehensive outline of the Regenerative Medicine market has been analyzed, which involves the valuation of the different organization in the global market.2.Developing trends in various Regenerative Medicine market segments and geological market.3.Substantial changes in market strategies and Regenerative Medicine market synopsis.4.Market methodologies and market stakes of major players in the Regenerative Medicine market.5.Existing and future dimensions of Regenerative Medicine market on the basis of both cost and volume point of view.6.Estimates of latest Regenerative Medicine Market Industry trends and advanced development.7.Major references for the new entrants for stability in the global and competitive market.

To describe and classify the market for Regenerative Medicine market

Delivers complete data associated with the major factors inducing growth of the global Regenerative Medicine market that includes drivers, restraints, opportunities, and trends. Studies and predicts the market volume and market stake of Regenerative Medicine market, related to volume and values. The Regenerative Medicine market report examines the market breakdown and anticipates the market volume related to volume and value, for geographical regions that include growth regions over the globe. Investigates competitive expansion, associated with product introduction, developmental stability and agreement & mergers occurring in the Regenerative Medicine market. Tactically portrays the competitive players functioning in the Regenerative Medicine market.

Delivers complete data associated with the major factors inducing growth of the global Regenerative Medicine market that includes drivers, restraints, opportunities, and trends. Studies and predicts the market volume and market stake of Regenerative Medicine market, related to volume and values. The Regenerative Medicine market report examines the market breakdown and anticipates the market volume related to volume and value, for geographical regions that include growth regions over the globe. Investigates competitive expansion, associated with product introduction, developmental stability and agreement & mergers occurring in the Regenerative Medicine market. Tactically portrays the competitive players functioning in the Regenerative Medicine market.

In this Regenerative Medicine market report study, scrutiny of dealers and distributors is specified along with contact information. Also, the Regenerative Medicine market report includes the manufacturing plants, Regenerative Medicine Market Industry details of imports and exports, demand and supply chain, their ability, worldwide productivity, and revenue. Lastly, it provides the data related to research findings, Regenerative Medicine Market data sources, conclusion, and appendix.

For Any Query on the Regenerative Medicine market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

See the article here:
Regenerative Medicine Market Research Report 2020 Includes 8-Year Forecasts due to the Impact of COVID-19 Adroit Market Research - The...

TOKYO--(BUSINESS WIRE)--LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine to initiate a joint research on the development of mitochondrial therapy for cardiac ischemicreperfusion injury.

Background of joint research

Ischemic heart disease (myocardial infarction and angina) still remains the leading cause of death in the world despite advances in treatment and prevention *1. Ischemia, the cause of these disorders, is a condition in which blood flow is temporarily blocked, interrupting the oxygen supply to the myocardial tissue and severely impairing its function. Blood reperfusion is required to recover tissue function. However, reperfusion causes an increase in intracellular calcium and reactive oxygen species (free radicals), which induce intracellular mitochondrial damage, cardiomyocyte necrosis, and arrhythmias, among other disorders.

The Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine is conducting basic and clinical research on regenerative medicine, severe heart failure, arrhythmia and ischemic heart disease, and has extensive experience in research on the diagnosis and treatment of various cardiovascular diseases such as ischemic heart disease, arrhythmia, valvular heart disease, cardiomyopathy, pulmonary hypertension and peripheral arterial disease.

LUCA Science is developing an innovative platform of highly functional mitochondrial therapy using proprietary technologies: LUCA Sciences mitochondria can be stored and delivered as a biopharmaceutical agent. The bioenergetics enhancement, tissue protection and cellular functional improvement from the mitochondria therapy is expected to reduce the size of myocardial infarction due to ischemia-reperfusion injury and provide therapeutic benefits for acute myocardial infarction.

Comment from Prof. Toyoaki Murohara at the Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine.

Mitochondria are very important organelles that produce energy in the cell. Until now, most research has been conducted to improve mitochondrial function using drugs, but this is a completely new and innovative research project that involves the direct administration of purified mitochondria into the body for therapeutic applications. We are planning to work with LUCA Science to study the effects of mitochondrial therapy on myocardial damage.

About LUCA Science

LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Mitochondria are the power plants in our cells that produce energy for our bodies. LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent. The advanced delivery system can be applied not just for mitochondria but also other compounds that can improve bioenergetics in specific cells or tissues.

LUCA Science recently completed $9.8 million Series A financing.

*1: World Health Organization (WHO) Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva, World Health Organization; 2018.https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

LUCA Science Inc.Name : LUCA Science Inc.Headquarters : 3-8-3, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-0023, JapanCEO : Rick C. Tsai DMD, MDEstablished : December 25th 2018Employees : 12URL : https://luca-science.com Business : Research and development of mitochondrial biopharmaceuticals

Go here to see the original:
LUCA Science Announces Joint Research With Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine on the...

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Regenerative Medicine Products Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Regenerative Medicine Products Market Overview

The Regenerative Medicine Products Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Regenerative Medicine Products market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Regenerative Medicine Products Market: Competitive Landscape

The Regenerative Medicine Products Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Regenerative Medicine Products Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Regenerative Medicine Products Market Segment by Type:

Regenerative Medicine Products Market Segment by Application:

Regenerative Medicine Products Market Regional overview:

In the report, experts analyze and forecast the Regenerative Medicine Products market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Regenerative Medicine Products Market Report:

Outlook analysis of the Regenerative Medicine Products market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Regenerative Medicine Products market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read the original:
Regenerative Medicine Products Market Size, Revenue, Share, Scope, Growth Rate And Forecast To 2027 - The Haitian-Caribbean News Network

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m. ET to review clinical data presented during the Plenary Scientific Session at the annual ASH Meeting and Exposition from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in patients with sickle cell disease and beta thalassemia. The presentation will include speakers from Vertex and CRISPR Therapeutics as well as Haydar Frangoul M.D., Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute, HCA Healthcares TriStar Centennial Medical Center, and a principal investigator in the CTX001 clinical studies.

The conference call will be webcast live and a link to the webcast can be accessed on the CRISPR Therapeutics website at https://crisprtx.gcs-web.com/events in the Investors section under Events and Presentations and on the Vertex website at http://www.vrtx.com in the "Investors" section. To access the call via phone, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the companies websites for approximately 30 days.

This meeting is not an official program of the ASH annual meeting.

About the CRISPR-Vertex CollaborationCRISPR Therapeutics and Vertex entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. CTX001 represents the first potential treatment to emerge from the joint research program. CRISPR Therapeutics and Vertex will jointly develop and commercialize CTX001 and equally share all research and development costs and profits worldwide.

Story continues

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Therapeutics Forward-Looking StatementThis press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics expectations about plans to review data presented at the annual ASH Meeting and Exposition from two ongoing Phase 1/2 clinical trials of CTX001 in patients with sickle cell disease and beta thalassemia, as well as the anticipated speakers participating in the investor webcast. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, existing and prospective investors are cautioned that forward-looking statements are inherently uncertain and not to place undue reliance on such statements, which speak only as of the date they are made. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential that preliminary data from any clinical trial not to be indicative of final trial results; the potential that clinical trial results may not support registration or further development; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology; and those risks and uncertainties described under the heading Risk Factors in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS word mark and design logo and CTX001 are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the expectations and plans to review data presented at the annual ASH meeting and exposition from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in patients with sickle cell disease and beta thalassemia, and the anticipated speakers participating in the investor webcast. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, the potential for data from a limited number of patients may not to be indicative of final clinical trial results, that data from the company's development programs, including its programs with its collaborators, may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at http://www.vrtx.com. You should not place undue reliance on these statements or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

CRISPR Therapeutics Investor Contact:Susan Kim, +1 617-307-7503susan.kim@crisprtx.com

CRISPR Therapeutics Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

Vertex Pharmaceuticals IncorporatedInvestors:Michael Partridge, +1 617-341-6108orZach Barber, +1 617-341-6470orBrenda Eustace, +1 617-341-6187

Media:mediainfo@vrtx.com orU.S.: +1 617-341-6992orHeather Nichols: +1 617-839-3607orInternational: +44 20 3204 5275

Go here to see the original:
CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and...

RICHARDSON, Texas--(BUSINESS WIRE)--Fuse Medical, Inc., (OTCPK: FZMD), an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it ranked number 43 on Deloittes Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. During the selected period Fuses revenue grew 3,935%.

Fuse Medicals Chief Executive Officer, Christopher C. Reeg, said, We are honored to be ranked on Deloittes Technology Fast 500 for the third year in a row, especially during these trying times with the COVID-19 pandemic. It is a privilege to be included with other fast-growing, innovative companies that are rapidly becoming leaders in their market sectors. This recognition further validates Fuses continued commitment to new product development and commercialization, while adding value to the healthcare system.

Mohana Dissanayake, Partner, Deloitte & Touche LLP commented, Each year the Technology Fast 500 listing validates how important technology innovation is to our daily lives. It was interesting to see this year that while software companies continued to dominate, biotech companies rose to the top of the winners list for the first time, demonstrating that new categories of innovation are accelerating in the pursuit of making life easier, safer, and more productive. We extend our congratulations to these well-deserved winnerswho all embody a spirit of curiosity, and a never-ending commitment to making technology advancements possible.

Fuse Medical moved up 46 spots on the winners list from where it previously ranked last year at 89. Overall, 2020 Technology Fast 500 companies achieved revenue growth ranging from 175 percent to 106,508 percent from 2016 to 2019, with median growth of 450 percent.

For more than 25 years, weve been honoring companies that define the cutting edge and this years Technology Fast 500 list is proof positive that technology from software and digital media platforms, to biotech truly does permeate so many facets of our lives, said Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader. We congratulate this years winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic.

About Deloittes 2019 Technology Fast 500

Now in its 26th year, Deloittes Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies both public and private in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Fuse Medical, Inc.

Fuse is an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace. We provide a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as, degenerative and deformity spine, orthobiologics and regenerative medicine products. For more information about the Company, or if youre interested in becoming a distributor of any Fuses products, please contact us at info@fusemedical.com or visit: http://www.fusemedical.com.

Forward Looking Statements

Certain statements in this press release, constitute forward-looking statements within the meaning of the federal securities laws. Words such as may, might, will, should, believe, expect, anticipate, estimate, continue, predict, forecast, project, plan, intend, or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Companys filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

Visit link:
Fuse Medical Ranked Number 43 Fastest Growing Company in North America on Deloitte's 2020 Technology Fast 500 - Business Wire

Global Regenerative Medicine Market report, published by Adroit Market Research, is an extensive compilation of the essential aspects of the global Regenerative Medicine market, assessed thoroughly by our team of researchers. The market intelligence report offers insightful data and information relevant to the market to acquaint the readers with the lucrative growth prospects existing in this industry, eventually helping them formulate effective business strategies. The global Regenerative Medicine market report has been methodically curated using industry-verified data to offer information concerned with the leading manufacturers and suppliers engaged in this sector. It further focuses on their pricing analysis, gross revenue, product portfolio, sales network & distribution channels, profit margins, and financial standing. Therefore, the latest research document includes competitive analysis, key market players, crucial industry-related facts & figures, sales revenue, product prices, gross margins, market shares, business strategies, dominant regions, and key developments.

Top Leading Key Players are:

Integra LifeSciences Corporation; MiMedx Group, Inc.; AstraZeneca; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Pfizer Inc.; and Baxter.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/52?utm_source=PT

Regenerative Medicine Market analysis covering the period 2020 to 2025. Industry coverage includes production capacities, trends and industry drivers. Market coverage includes international trade, segmental drivers, volumes, market prices and market values. The key focus of the report is a detailed look at historic, current and projected future volumes in the primary market segments. The report also presents a thorough qualitative and quantitative data pertaining to the projected impact of these factors on markets future growth prospects. With the inclusive market data concerning the key elements and segments of the global Regenerative Medicine market that can influence the growth prospects of the market, the report makes for a highly informative document. The Regenerative Medicine Market report displays the production, consumption, revenue, gross margin, cost, market share, CAGR, and market impacting variables of the Regenerative Medicine industry and forecast to 2025, from 2020.

For in-depth analysis and thorough understanding, the report presents a demand for individual segment in each region. It demonstrates various segments B2B, B2C, C2C and sub-segments Manufacturing, Consumer Goods, Retail, Automotive, Food and Beverage, Other of the global Regenerative Medicine market. The global Regenerative Medicine market report explains in-depth about the quantitative as well as the qualitative scenario of the market. The global Regenerative Medicine market report delivers the precise analytical information that explains the future growth trend to be followed by the global Regenerative Medicine market, based on the past and current situation of the market. In addition, the global Regenerative Medicine market report delivers concise information about the federal regulations and policies that may indirectly affect market growth as well as the financial state. The situation of the global market at the global and regional level is also described in the global Regenerative Medicine market report through geographical segmentation.

Browse complete Regenerative Medicine market report description and TOC @ https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market?utm_source=PT

The research on the Regenerative Medicine market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Regenerative Medicine market on the basis of end user, product type, application, and demography for the forecast period [emailprotected] Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics. This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Regenerative Medicine market.

Regenerative Medicine Market research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers, and challenges. The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used expert techniques for analyzing the Regenerative Medicine Market; it also offers an examination of the global market. To make the report more potent and easy to understand, it consists of infographics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

The research report on the global Regenerative Medicine market offers a comprehensive analysis, synthesis, and interpretation of data gathered about the Regenerative Medicine market from the number of reliable sources. In addition, the information has analyzed with the help of primary as well as secondary research methodologies to offer a holistic view of the target market. Likewise, the Regenerative Medicine market report offers an in-house analysis of global economic conditions and related economic factors and indicators to evaluate their impact on the Regenerative Medicine market historically. The report provides a broad segmentation of the market by categorizing the market into application, type, and geographical regions. The Regenerative Medicine market report delivers the growth prospects as well as the current scenario of the market. In addition, to assess the market size, the global Regenerative Medicine market report offers a brief outlook of the market by synthesis, study, and addition of data form the number of sources.

For More Information or Query or Customization Before Buying, Visit at @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52?utm_source=PT

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more here:
Regenerative Medicine Market 2020 Global Size, Industry Applications, Sales Revenue, Share, Recent Trends, Competitive Landscape, With Regional...

Regenerative medicine is a rapidly growing but still largely experimental field that takes a new approach to treating disease. It attempts to restore health by rejuvenating, repairing or replacingdamaged or degenerating cells, tissues and organs. The goal is to restore form and function by relying on the body's ability to heal itself. The potential to find cures, improve care outcomes and boost quality of life stretches to a vast menu of opportunities throughout the body and throughout life. The tools to reach these goals are diverse. They're often based on various types of stem cells. These are special cells that can divide and multiply to produce any type of the more specialized cells in the body, and can be coaxed to promote body healing.

Principles of regenerative medicine are already being used in medical practice with improvements in bone marrow transplantation, treatment for some cancers and early prevention of congenital lung deformities even before birth. Researchers and doctors are developing regenerative medicine techniques to ensure better ways to treat a range of medical problems including heart disease, arthritis, diabetes, stroke and dementia.

Significant investment is fueling the growth of regenerative science and its application in medical care. Mayo Clinic has established a Center for Regenerative Medicine. The National Institutes of Health, with funding from Congress, has established the Regenerative Medicine Innovation Project. Still, the field is young and most related work happens in the laboratory or in clinical trials rather than in a hospital bed. The ethical dimensions of implementing...

Read more from the original source:
Regenerative medicine - Mayo Clinic

Sanford Health a history of innovating and leading the way in new research.

Something that grabbed the attention of the NFL Alumni Association.

The NFL Alumni Association is a non-profit that looks to support retired NFL athletes and cheerleaders after their initial careers are over.

Because of the strenuous activity put on their bodies, many athletes walk away from the sport with nagging injuries without the option for care. This has led the NFL Alumni to seek out innovators in the world of health care.

Recently, Dr. David Pearce, Sanford Health president for innovation, research and World Clinic, spoke on regenerative medicine at a congressional briefing. His expertise prompted Kyle Richardson and Billy Davis, co-directors of health care initiatives for the NFL Alumni Association, to inquire about regenerative medicine and how it may serve retired athletes.

More: NFL Alumni tour Sanford, discuss regenerative medicine

As Dr. Pearce told Sanford Health News, its a complicated term, but regenerative medicine is essentially about healing. Dr. Pearce explains that regenerative healing takes something from your own body to heal a wound or an injury.

Im going to give you an example: if you cut yourself right now, it heals, right? The components within your body have the ability to heal an injury, such as a cut. If we twist our ankle and we get swelling, our body reacts and heals that injury. Regenerative medicine is about accelerating that healing so, taking a component of your body, and accelerating that healing and making it better.

Not only for retired athletes, this form of therapy could benefit everyone as they age.

As we get older, we start to deteriorate. So, we can harness our own body to maybe take some of those components that would be used to fix an injury to actually slow down the aging process and the wear and tear on joints, partiucularly in orthopedics.

Thats one of the highlighted areas that we are studying right now. As your knees grind away and you get arthritis, regenerative medicine is about taking some of those healing components to help regenerate and slow down that process, to heal those aches and pains, said Dr. Pearce.

Tiffany Facile is a research development partner at Sanford Health, and soon-to-be director of regenerative medicine at Sanford Health.

She says its imperative this medicine develops through the science of clinical trials.

Some common misconceptions are that regenerative medicine therapies are risky. There is some risk to procedures when using autologous or your own cells, but studies that are currently running should reduce the safety concerns.

Dr. Pearce echos Facile, warning of bad actors who offer products which have no regenerative capacity.

He says theres also a misconception associated with these therapies because theyre not approved by the FDA. However, Sanford Healths clinical trials have been approved.

What were doing at Sanford, is were taking those components of the body, working with the FDA and saying, its safe to do this. Our early work in a clinical study has demonstrated safety and efficacy with rotator cuff injuries. Were having remarkable results in terms of treating some of these injuries.

Another misconception revolves around stem cells. Both Facile and Dr. Pearce say regenerative medicine has not yet determined if stem cells in your body have the ability to signal other cells for repair.

We hear about embryonic stem cells and fetal stem cells; we dont do anything with that. First of all, its not very ethical. Secondly, theres no science to show that they can have regenerative capabilities, said Dr. Pearce.

Dr. Pearce says regenerative medicine can be used to heal nagging injuries, whether its for athletes or not.

Right now were taking cells from around the fat of your abdomen region, which is rich in a type of stem cell called adipose derived regenerative cells, and were relocating them to help heal rotator cuff tears, help to heal osteoarthritis in the knee, elbow, wrist, ankle, and hip, he said.

Dr. Pearce says theyre doing this research, under the auspices of what we call a clinical trial, and where we follow patients to hopefully demonstrate safety and efficacy.

Because of the misconceptions surrounding this form of medicine, we have to do this right, because its not a regulated industry just yet. The food and drug administration oversees what were doing with respect to that.

We know that we can help heal damaged heart cells. We know we can help healing cells that have been damaged by a stroke. Were already taking the next step in working on those protocols where we can do some trials and look to see if we can heal other injuries in the body. These cells have the ability to heal anything in the body, if directed in the right way, said Dr. Pearce.

Dr. Pearce says Sanford Health is the first health system in the nation to get approval for the use of regenerative medicine in treating orthopedic injuries.

Were hoping to be a leader not just in the Midwest, were hoping to be a leader nationally, where we can teach other health systems how to administer these treatments by either going there and training people, or us becoming really a hub for that.

As for the future of regenerative medicine, Dr. Pearce says it could have an impact in how quickly athletes recover from injuries.

I think for athletes that return to play, this will have a huge impact in terms of how we can help people turn around. More importantly, as they retire, we know theres a lot of grinding and wear and tear on their bodies. Well be able to manage that much more appropriately, said Dr. Pearce.

This form of medicine can also help non-athletes manage any nagging aches and pains.

For those whove got some aches and pains here and there, well be able to use this to really alleviate some of the pain and aches we have, and manage that much better.

Posted In Innovations, Orthopedics, Research, Specialty Care, Sports Medicine, World Clinic

Read more from the original source:
What is regenerative medicine? - Sanford Health News

Regenerative medicine, the application of treatments developed to replace tissues damaged by injury or disease. These treatments may involve the use of biochemical techniques to induce tissue regeneration directly at the site of damage or the use of transplantation techniques employing differentiated cells or stem cells, either alone or as part of a bioartificial tissue. Bioartificial tissues are made by seeding cells onto natural or biomimetic scaffolds (see tissue engineering). Natural scaffolds are the total extracellular matrixes (ECMs) of decellularized tissues or organs. In contrast, biomimetic scaffolds may be composed of natural materials, such as collagen or proteoglycans (proteins with long chains of carbohydrate), or built from artificial materials, such as metals, ceramics, or polyester polymers. Cells used for transplants and bioartificial tissues are almost always autogeneic (self) to avoid rejection by the patients immune system. The use of allogeneic (nonself) cells carries a high risk of immune rejection and therefore requires tissue matching between donor and recipient and involves the administration of immunosuppressive drugs.

A scientist conducting research on stem cells.

A variety of autogeneic and allogeneic cell and bioartificial tissue transplantations have been performed. Examples of autogeneic transplants using differentiated cells include blood transfusion with frozen stores of the patients own blood and repair of the articular cartilage of the knee with the patients own articular chondrocytes (cartilage cells) that have been expanded in vitro (amplified in number using cell culture techniques in a laboratory). An example of a tissue that has been generated for autogeneic transplant is the human mandible (lower jaw). Functional bioartificial mandibles are made by seeding autogeneic bone marrow cells onto a titanium mesh scaffold loaded with bovine bone matrix, a type of extracellular matrix that has proved valuable in regenerative medicine for its ability to promote cell adhesion and proliferation in transplantable bone tissues. Functional bioartificial bladders also have been successfully implanted into patients. Bioartificial bladders are made by seeding a biodegradable polyester scaffold with autogeneic urinary epithelial cells and smooth muscle cells.

Another example of a tissue used successfully in an autogeneic transplant is a bioartificial bronchus, which was generated to replace damaged tissue in a patient affected by tuberculosis. The bioartificial bronchus was constructed from an ECM scaffold of a section of bronchial tissue taken from a donor cadaver. Differentiated epithelial cells isolated from the patient and chondrocytes derived from mesenchymal stem cells collected from the patients bone marrow were seeded onto the scaffold.

There are few clinical examples of allogeneic cell and bioartificial tissue transplants. The two most common allogeneic transplants are blood-group-matched blood transfusion and bone marrow transplant. Allogeneic bone marrow transplants are often performed following high-dose chemotherapy, which is used to destroy all the cells in the hematopoietic system in order to ensure that all cancer-causing cells are killed. (The hematopoietic system is contained within the bone marrow and is responsible for generating all the cells of the blood and immune system.) This type of bone marrow transplant is associated with a high risk of graft-versus-host disease, in which the donor marrow cells attack the recipients tissues. Another type of allogeneic transplant involves the islets of Langerhans, which contain the insulin-producing cells of the body. This type of tissue can be transplanted from cadavers to patients with diabetes mellitus, but recipients require immunosuppression therapy to survive.

Cell transplant experiments with paralyzed mice, pigs, and nonhuman primates demonstrated that Schwann cells (the myelin-producing cells that insulate nerve axons) injected into acutely injured spinal cord tissue could restore about 70 percent of the tissues functional capacity, thereby partially reversing paralysis.

Studies on experimental animals are aimed at understanding ways in which autogeneic or allogeneic adult stem cells can be used to regenerate damaged cardiovascular, neural, and musculoskeletal tissues in humans. Among adult stem cells that have shown promise in this area are satellite cells, which occur in skeletal muscle fibres in animals and humans. When injected into mice affected by dystrophy, a condition characterized by the progressive degeneration of muscle tissue, satellite cells stimulate the regeneration of normal muscle fibres. Ulcerative colitis in mice was treated successfully with intestinal organoids (organlike tissues) derived from adult stem cells of the large intestine. When introduced into the colon, the organoids attached to damaged tissue and generated a normal-appearing intestinal lining.

In many cases, however, adult stem cells such as satellite cells have not been easily harvested from their native tissues, and they have been difficult to culture in the laboratory. In contrast, embryonic stem cells (ESCs) can be harvested once and cultured indefinitely. Moreover, ESCs are pluripotent, meaning that they can be directed to differentiate into any cell type, which makes them an ideal cell source for regenerative medicine.

Studies of animal ESC derivatives have demonstrated that these cells are capable of regenerating tissues of the central nervous system, heart, skeletal muscle, and pancreas. Derivatives of human ESCs used in animal models have produced similar results. For example, cardiac stem cells from heart-failure patients were engineered to express a protein (Pim-1) that promotes cell survival and proliferation. When these cells were injected into mice that had experienced myocardial infarction (heart attack), the cells were found to enhance the repair of injured heart muscle tissue. Likewise, heart muscle cells (cardiomyocytes) derived from human ESCs improved the function of injured heart muscle tissue in guinea pigs.

Derivatives of human ESCs are likely to produce similar results in humans, although these cells have not been used clinically and could be subject to immune rejection by recipients. The question of immune rejection was bypassed by the discovery in 2007 that adult somatic cells (e.g., skin and liver cells) can be converted to ESCs. This is accomplished by transfecting (infecting) the adult cells with viral vectors carrying genes that encode transcription factor proteins capable of reprogramming the adult cells into pluripotent stem cells. Examples of these factors include Oct-4 (octamer 4), Sox-2 (sex-determining region Y box 2), Klf-4 (Kruppel-like factor 4), and Nanog. Reprogrammed adult cells, known as induced pluripotent stem (iPS) cells, are potential autogeneic sources for cell transplantation and bioartificial tissue construction. Such cells have since been created from the skin cells of patients suffering from amyotrophic lateral sclerosis (ALS) and Alzheimer disease and have been used as human models for the exploration of disease mechanisms and the screening of potential new drugs. In one such model, neurons derived from human iPS cells were shown to promote recovery of stroke-damaged brain tissue in mice and rats, and, in another, cardiomyocytes derived from human iPS cells successfully integrated into damaged heart tissue following their injection into rat hearts. These successes indicated that iPS cells could serve as a cell source for tissue regeneration or bioartificial tissue construction.

See the original post:
regenerative medicine | Definition, Stem Cells, & Facts ...

LONDON--(BUSINESS WIRE)--Increasing investment in R&D, and a steady rise in the prevalence of chronic diseases, has fueled demand for regenerative medicine. Additionally, the upsurge in M&A alliances and strategic partnerships has significantly propelled growth in regenerative medicine. However, there are various challenges with regenerative medicine manufacturing, including high and rising manufacturing expenses, the quality of designs, issues with supply chain and biomaterials.

Request a free proposal to know how Infiniti is supporting the regenerative medicine market to overcome the pressing manufacturing challenges.

The regenerative medicine market has significant benefits for big pharma and is expected to grow significantly. Experts expect a rapid pace of development in the regenerative medicine market over the next decade. The increasing investments in R&D activities and the rising incidence of chronic diseases in the US are key factors in fueling demand. Further, strategic alliances among vendors will have a significant impact on the overall market growth and innovation. Several roadblocks to commercially viable therapies have made it challenging to deliver regenerative medicines. In their latest article, Infinitis industry analysts highlight some of the most critical and pressing manufacturing challenges in regenerative medicine products.

Regenerative medicine is currently the hive of innovation in modern science with far-reaching benefits for big pharma, healthcare systems, and patient outcomes. We can expect a rapid pace of development in the US regenerative medicine market over the next decade, says a product development strategy expert at Infiniti Research.

Infinitis industry analysts highlighted the following four key challenges in the regenerative medicine market:

Speak with our industry experts for more insights on the major challenges in the regenerative medicine market and how companies can capitalize on the forecasted growth.

About Infiniti Research

Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies. To know more, visit: https://www.infinitiresearch.com/about-us

See the original post:
What Pressing Challenges Does the Pharmaceutical Industry Face with Regenerative Medicine Manufacturing? Infiniti's Industry Analysts Highlight and...

Share This Article:A stem cell research center at UC Davis. Courtesy California Institute for Regenerative MedicineBy Barbara Feder Ostrov | CalMatters

Californias stem cell research agency was supposed to be winding down its operations right about now, after a 16-year run and hundreds of millions in grants to scientists researching cutting-edge treatments for diabetes, cancer, Alzheimers and other diseases.

Support Times of San Diego's growthwith a small monthly contribution

Instead, the taxpayer-supported California Institute for Regenerative Medicine will get a $5.5 billion reboot after voters earlier this month narrowly passed the Proposition 14bond measure. The overall cost of the bonds with interest will total about $7.8 billion.

Were thrilled that California voters saw fit to continue the work weve done, said Jonathan Thomas, chair of the agencys governing board. California has always had a frontier mentality and a love for the cutting edge, and the work that CIRM has done has put it on the very forefront of regenerative medicine.

Even with Californias economy in a coronavirus-induced tailspin and somescientists arguingthat stem cell research no longer needs taxpayer support,Prop. 14passed with 51 percent of the vote after well-financed supporters pourednearly $21 millioninto the Yes on 14 campaign. The measure was essentially a rerun of Proposition 71, which California voters approved in 2004 after a since-revoked federal ban on embryonic stem cell research.

The cash infusion is expected to keep the institute running for another 10 to 15 years, although the agency will see some significant changes under Prop. 14.

The institute also must contend with longstanding concerns over conflicts of interest that have dogged it since its inception, observers say. About 80% of the money distributed has gone to universities and companies tied to agency board members, according to an analysisby longtime agency watchdog David Jensen, a former Sacramento Bee journalist who runs theCalifornia Stem Cell Reportblog and wrote abookon the institute.

Prop. 14 allows the agency to fund a wider array of research projects even some that dont involve stem cells, but instead are related to genetics, personalized medicine and aging.

Thats necessary because the field has evolved, said Paul Knoepfler, a UC Davis professor of cell biology who studies the role of stem cells in cancer and writes a stem cell blog. He received a 2009 grant from the institute.

Stem cells are interesting and important, but there are going to be a lot of new therapies in the next 10 years that are not stem-cell centric, Knoepfler said.

Other changes for the agency include:

Ysabel Duron, who joined the institutes board late last year, said she sees her role as promoting equity in opportunities for both researchers and patients and ensuring that treatments resulting from the research can benefit all Californians.

Researchers in particular need to boost the diversity of patients in their clinical trials and do a better job communicating the value of their work to the public, Duron said, noting that nearly 40% of Californians are Latino.

We need to keep researchers feet to the fire, said Duron, a former television journalist and founder of the Latino Cancer Institute. They need to show us a plan and we need to reward them.

To date, the agency has funded 64 clinical trials of treatments for many types of cancer, sickle cell disease, spinal cord injuries, diabetes, kidney disease and amyotrophic lateral sclerosis, commonlyknown as Lou Gehrigs disease.But the most advanced trials involve therapies for relatively rare conditions, such asSevere Combined Immunodeficiency known as the bubble baby disease, Jensen noted. That therapy is being reviewed by the FDA but has not yet been approved.

Cancer, heart disease these are the big killers. Thats what most people are interested in, Jensen said. You can fund something for a rare disease, but that doesnt affect the majority of Californians.

And, Jensen asks, what will happen after the agency runs out of money again? Will taxpayers once again be asked to refill its coffers? There was hope when the agency began that revenues from successful treatments would sustain its grant-making in the years to come, but the institute has only received a few hundred thousand dollars, not nearly enough to become self-sustaining without taxpayer support, according to theLegislative Analysts Office.

The sustainability issue is important and its hard to address, Jensen said. The money doesnt last forever.

Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 was last modified: November 27th, 2020 by Editor

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Here is the original post:
Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 - Times of San Diego

Researchers at Stanford Burnham Prebys Medical Discovery Institute recently developed a drug that can lure stem cells to impaired tissue and enhance the efficacy of treatment.

This is considered a "scientific first," not to mention a major advance for the field of regenerative drugs. Such a discovery, which theProceedings of the National Academy of Sciences or PNASpublished could enhance the present stem cell treatments developed to cure such neurological disorders like stroke, spinal cord injury, ALS or other amyotrophic lateral sclerosis, as well as other neurodegenerative diseases -- and have their use expanded to new conditions such as arthritis or heart disease.

In the study, toxic or green cells disappeared when mice with a neurodegenerative condition were given both therapeutic or red cells and the drug SDV1a, which matched with delayed onset of symptoms and longer lives.

(Photo : Stem Cell Research via Getty Images)In this undated handout photo released by the Institute for Stem Cell Research in 2005, neurons (red) and astrocytes (green), which can be made from neural stem cells, are seen.

Results Suggesting Efficacy of the Drug

The study results proposed that SDV1a can be used to enhance the stem cell treatments' efficacy. According to Evan Snyder, MD, PhD, theCenter for Stem Cells & Regenerative Medicine at Stanford Burnham Prebysprofessor and director, "the ability to instruct a stem cell where to go in the body, or to a particular region of a given organ is the 'Holy Grail' for regenerative medicine.

Snyder, who's also the senior author of the study, added, now, for the first time, stem cells can be directed to a desired area and focus its therapeutic effect.

Almost a decade-and-a-half back, the senior author, together with his team, found that stem cells are drawn to infection, a biological 'fire alarm' indicating that damage has taken place.

Nevertheless, using inflammation as a healing appeal is not possible since an inflammation environment can be dangerous to the body. Hence, researchers have been searching for mechanisms to help in the migration of stem cells or 'home' to the body's desired areas.

Such a mechanism or tool, according to reports on this new finding, would be a great contributor for disorders in which preliminary inflammatory indicators disappear over time, like chronic spinal cord injury or stroke, and conditions where the inflammation's role is not clearly understood, like heart disease, for one.

Fortunately, after decades of investing in stem cell science, scientists are now making "tremendous progress," saidCalifornia Institute for Regenerative Medicine or CIRMpresident and CEO Maria Millan, MD said, in their understanding of the manner such cells work and the manner they can be attached to help reverse disease or an injury.

The CIRM partially funded this new study. Millan also said, Snyder's group has identified a medicine that could enhance "the ability of neural stem cells to home to sites of injury and initiate repair."

More so, the president and CEO also explained, the drug candidate could help fast-track the stem cell treatments' development, specifically for conditions including Alzheimer's disease and spinal cord injury.

In the research, study investigators modified an inflammatory molecule called CXCL12, which the Snyder's group discovered previously, could guide healing stem cells to areas that need repair to develop the SDV1a.

As such, this new medicine works by improving stem cell binding and minimizing inflammatory indicating and can be injected anywhere to attract stem cells to a particular site without causing any inflammation.

Since such inflammation can be dangerous, Snyder explained, they modified CXL12 by "tripping away the risky beat and maximizing the good bit."

Now, he added, they have a drug, drawing stem cells to an area of pathology, but not creating or worsening the unwanted infection.

"Now, we have a drug that draws stem cells to a region of pathology, but without creating or worsening unwanted inflammation."

Furthermore, to present that the new medication can improve the effectiveness of stem cell therapy, the scientists implanted SDV1a and human neural stem cells into the brains of mice thatSandhoff disease, a neurodegenerative disease.

The scientists have already started testing the ability of SDV1a to enhance stem cell therapy in a mouse model of Lou Gehrig's disease, also known as ALS, which results from progressive loss of motor neurons in the brain.

Snyder said they are optimistic that the mechanism of action of this new drug may potentially benefit various neurodegenerative disorders and non-neurological conditions like arthritis, heart disease, and even brain cancer.

Interestingly, he also explained, since CXL12 and its receptor is said to be implicated in cytokine storm that exemplifies severeCOVID-19, some of their understandings of how to constrain infection without controlling other normal procedures selectively may be helpful in that field, as well.

RELATED:'Marie Kondo' Protein in Fruit Fly Embryos Helps Them Keep Organized

Check out more news and information onStem Cellsin Science Times.

Original post:
Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times